4 min 
Your Competitive Edge Depends on Faster BD Decisions
Biotech innovation is exploding with new modalities, and more early-stage startups and external assets than ever before. For business development (BD) teams in pharma, this creates a simple reality: huge biotech opportunities but the challenge to evaluate them and take action faster than competitors – or risk missed deals and a weakened competitive edge.
Yet traditional methods simply can’t keep up. Most business development in pharma teams are still working with:
- Time-consuming data mining and spreadsheet analysis.
- Expensive, one-off consulting reports.
- Excel-based forecasting that can’t scale.
- Fragmented data sources that fail to tell the whole story.
This model is holding business development teams back from evaluating promising assets with the speed and confidence they need to make a quick decision.
Too Much to Evaluate, Not Enough Capacity
As a result, BD leaders face three systemic challenges:
- Limited capacity – With limited time and expensive evaluations, only a few assets can be assessed rigorously each quarter.
- Investment uncertainty – Without real-time data or predictive insights, decision-making often rests on incomplete information.
- Lost advantage – Valuable biotech opportunities are missed simply because competitors move faster.
To overcome this, BD leaders need a way to bring everything together – turning complex data into accurate, timely intelligence that supports fast, confident decisions.
That’s where smarter, data-driven evaluation comes in.
Tovana Opportunity Assessment: Faster, Smarter Evaluation for Business Development in Pharma
Imagine being able to size markets, forecast revenue, and model risk in days rather than weeks.
That’s the promise of combining:
- Real-world claims data (diagnosis, treatment, adherence)
- AI-powered forecasting and simulation
- Modular analytics adaptable to any product or therapeutic area.
Tovana Opportunity Assessment was built specifically for these realities. It delivers real-world insights, faster – empowering pharma business development and investment teams to size opportunities, reduce risk, and make confident, strategic decisions.
- Speed – Cut evaluation time from weeks to days.
- Depth – Access 360° market views with patient-level analysis.
- Clarity – Visualize insights and run scenario modeling.
- Scale – Assess more opportunities without growing the team.
- Cost-efficiency – Move beyond expensive one-off, static evaluations to unlimited evaluations under a fixed license.
For business development in pharma,Tovana’s Opportunity Assessment provides real-time foresight into markets, patients, and revenue potential. This means teams can now focus on the decisions that matter and evaluate more opportunities without sacrificing depth or rigor.
The Intelligence Behind Tovana Opportunity Assessment
At the heart of Tovana Opportunity Assessment is a predictive analytics engine purpose-built for BD that automates evaluation through:
- AI-trained forecasting models based on real-world diagnosis, treatment, and adherence patterns.
- Automated scenario modeling (Monte Carlo simulations) to quantify uncertainty and range outcomes.
- Data normalization and ingestion pipelines that clean and structure claims data, epidemiology inputs, and historical analogs.
Tovana Opportunity Assessment delivers all the key components needed to evaluate business development in pharma opportunities quickly and rigorously. It combines the tools BD teams would normally cobble together over weeks in one unified solution:
- Market Size & Mapping
Define opportunities using real-world claims data, epidemiology-based forecasting, and validated forecasting methodologies to estimate patient volumes, therapeutic overlap, and revenue potential. - Patient-Based Forecasting
Predict revenue based on how patients are diagnosed, treated, and adhere to therapy with diagnostic analytics that track populations and identify high-value HCP segments. - Monte Carlo Simulation
Quantify uncertainty with automated scenario modeling to assess upside and downside cases using historical analogs and competitive intensity. - Natural Patient History
Visualize patient journeys from symptom to diagnosis to treatment – surfacing unmet needs, access gaps, and treatment trends. - Sales Force Sizing
Estimate the optimal field footprint by mapping market coverage needs, existing representative deployment, and geographic treatment density. - Epidemiology Analysis
Rapidly extract and structure epidemiological data from published studies and public sources to establish population assumptions for both rare and common conditions.
Each capability is modular – so business development in pharma teams can adapt evaluations to the product, therapeutic area, or stage of investment.
What Business Development in Pharma Teams Can Do Now
By embedding the Tovana Opportunity Assessment solution into their evaluation process, teams can now evaluate more opportunities, cut costs, and make faster, evidence-based decisions:
- Evaluate 5–10x more opportunities with the same resources.
- Lower evaluation costs by > 50%.
- Say “no” earlier based on consistent, data-backed criteria.
- Say “yes” faster with a complete view of market size, forecasted revenue, risk, and operational fit.
- Bring stakeholders on board sooner – with clear, visual assessments that make complex evaluations easier to align around.
For example, one of Verix’s global pharma clients shortened evaluation cycles from 6–8 weeks to just 2–3 days. They replaced costly one-off assessments with unlimited evaluations under a fixed license and moved from guesswork to data-backed, consistent decision-making.
As their US VP of Commercial Strategy, Partnerships, and BD&L put it:
“What we used to do in months of analysis for a single therapeutic, we can now do with Tovana in a couple of days – analyzing every aspect of an opportunity, including market potential, competition, required salesforce and more.”
Download the case study here.
Why Adopting a New Approach to Biotech BD Opportunity Assessment Is Essential
The pace of biotech innovation is only accelerating – and so is the competition. To stay ahead, BD teams need a faster, more scalable way to evaluate opportunities with confidence. Traditional methods are no longer enough, being too slow, too manual, and too expensive to keep up.
Tovana Opportunity Assessment provides BD teams with a cost-effective, repeatable approach to assess business development in pharma opportunities – helping them move quickly, reduce risk, and stay ahead of the competition.
Learn more or schedule a walkthrough to see how the Tovana Opportunity Assessment solution can help your team evaluate more opportunities with speed and confidence.
